Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
See tonight’s solar storm unfold across the world - 2Firefighters rescue two Israelis trapped in vehicles on flooded roads in West Bank
- 3ByHeart infant formula recall tied to botulism outbreak puts parents on edge
- 4Vote in favor of Your Fantasy Vehicle: Which Notable Model Catches Your Heart?
- 5Storm Goretti sweeps United Kingdom, France with winds over 120 mph
- Ukraine demands army of 800,000 under peace plan
- 'A prank': Israel Police detain suspect for shooting rubber bullets at Ashkelon kindergarten
- Why home maintenance deserves a spot in the annual health and budget plans
- Make your choice for the sweet that transports you to its nation of beginning!
- Nestlé recalls infant formula in 49 countries. See list.
- I visited the largest collection of public telescopes in the US in Oregon's high desert, and the dark skies blew me away
- As infant botulism cases climb to 31, recalled ByHeart baby formula is still on some store shelves
- When Would it be a good idea for you to Look for Help from a Criminal Legal counselor?
- Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion
